New developments in prostate cancer biomarkers

Purpose of review: The initial management of localized prostate cancer is increasingly complex with the identification of a growing number of prognostic subgroups. Molecular and genetic biomarkers have been proposed to help clinicians and patients navigate treatment decisions. Recent findings: Three commercially available tests, the Genomic Prostate score, Cell Cycle Progression score, and Genomic Classifier appear to currently have the most supporting data for their use in localized prostate cancer. All three have been shown to identify men at higher risk for poor outcome following radical prostatectomy in retrospective studies whereas the first two have also shown promise in addressing which men might be appropriate for active surveillance. Only the Genomic Classifier has data supporting its use as a predictive marker in addition to a prognostic marker. Summary: Over the past several years, the management of localized prostate cancer has seen the development of several novel biomarkers aimed at improving decision making. Although a lack of prospective validation makes it challenging to know how best to change management based on the results from any of the tests, the growing body of retrospective data suggests significant promise in this arena.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research

Related Links:

The next generation Androgen receptor (AR)-targeted therapies are now in widespread clinical use and prolong prostate cancer (CaP) patient survival. However, the therapies are not curative due to diverse range of resistance mechanisms. AR variants (AR-V), one major mechanism of resistance, has recently gained momentum. Here, we found that GABARAPL1 knockdown inhibits the growth of AR-positive LNCaP and CWR22rv1 CaP cells in vitro and in vivo, decreases AR/AR-V transcription activity and AR nuclear translocation. Pulldown assay shows that both of Full-length (FL)-AR and AR-V were able to interact with GABARAPL1, suggesting ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): R. Rodrigues Fonseca, R. Lains Mota, I. Peyroteo, A. Bilé Silva, J.C. Santos, F. Alpoim Lopes, A. Covita, A. Canhoto, P. Monteiro, R. Nogueira, L. Abranches Monteiro
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): D. Meijer, B.H.E. Jansen, M. Wondergem, S. Srbljin, A.E. Vellekoop, A. Keizer, O.S. Hoekstra, J.A. Nieuwenhuijzen, D.E. Oprea-Lager, A.N. Vis
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): B.H.E. Jansen, M. Wondergem, F.M. Van Der Zant, T.M. Van Der Sluis, R.J.J. Knol, L.W.M. Van Kalmthout, O. Hoekstra, R.J.A. Van Moorselaar, D.E. Oprea-Lager, A.N. Vis
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): G. Lughezzani, J.G. Pereira, A. Sánchez, F. Staerman, H. Cash, L. Lopez, J. Rouffilange, R. Gaston, E. Klein, R. Abouassaly, A. El-Shefai, L. Klotz, G. Eure
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Purpose High-intensity interval training (HIIT) is a time-efficient and promising tool for enhancing physical fitness. However, there is lack of research concerning safety and feasibility of HIIT in cancer survivors. Therefore, two different HIIT protocols were investigated in terms of safety, feasibility, and acute exercise responses. Methods Forty cancer survivors (20 breast and 20 prostate cancer survivors, 62.9 ± 9.2 yr, BMI 27.4 ± 3.9 kg·m−2, 6 to 52 wk after the end of primary therapy) completed a maximal cardiopulmonary exercise test and two HIIT protocols on a cycle ergometer: 10 &ti...
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: CLINICAL SCIENCES Source Type: research
Publication date: November 2019Source: Journal of Comparative Pathology, Volume 173Author(s): T.H.M. Vargas, L.H. Pulz, D.G. Ferro, R.A. Sobral, M.A.F.A. Venturini, H.L. Corrêa, R.F. StrefezziSummaryMalignant melanomas (MMs) represent 7% of all malignant neoplasms in dogs. Oral melanocytic neoplasms are often malignant and associated with poor prognosis. There are no universally accepted prognostic markers for canine oral melanoma. Galectin (Gal)-3 is a prognostic marker for human neoplasms such as thyroid, gastric, colorectal and prostate cancers. The protein is related to processes that favour cancer progression, s...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsNon-tissue diagnosis of prostate cancer, while rare, is not outside normal clinical practice and is strongly associated with advanced patient age, higher clinical stage, multiple comorbidities, and very high PSA levels.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: The self-reported benefits of physiotherapy for SUI symptoms did not differ significantly between the two types of prostatectomy surgery at 2 years post-surgery. PMID: 31719716 [PubMed]
Source: Physiotherapy Canada - Category: Physiotherapy Authors: Tags: Physiother Can Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Prostate Cancer | Study